IDXX
IDEXX LABORATORIES INC /DE
NASDAQ · Healthcare · Medical - Diagnostics & Research · US
$555.80
−0.81%Oct 1, 2026, 15:30 UTC
IDEXX Laboratories scheduled the release of its 2026 third quarter financial results for Monday, November 2, 2026, before market open, with an analyst conference call at 8:30 a.m. ET that day.
Source:Sep 30, 2026, 13:00 UTC
IDEXX Laboratories acquired CoVetAI Inc., prompting Chicago Pacific Founders to exit its investment in the company.
Source:Sep 17, 2026, 07:00 UTC
IDEXX Laboratories expanded its Faecal Dx antigen testing platform in the United Kingdom with taeniid tapeworm detection for broader intestinal parasite screening.
Source:Sep 16, 2026, 11:00 UTC
IDEXX Laboratories acquired CoVetAI to advance veterinary workflow intelligence.
Source:Aug 14, 2026, 18:03 UTC
IDEXX Laboratories outlined at its 2026 Investor Day a pipeline of diagnostic, software, and AI offerings, including cancer tests, targeting a $45 billion global companion-animal testing opportunity.
Source:Aug 11, 2026, 11:00 UTC
IDEXX launched the Catalyst proBNP Test, the first and only dual-species point-of-care NT-proBNP assay for cardiac assessment in dogs and cats, at its Westbrook, Maine facility.
Source:Aug 4, 2026, 10:30 UTC
IDEXX Laboratories reported second quarter 2026 revenues of $1,217 million, up 10% as reported and 9% organic, with growth across its business segments.
Jun 25, 2026, 00:00 UTC
Jonathan J. Mazelsky was appointed as a Class II director of Insulet Corp, effective July 1, 2026.